Advice
following an abbreviated submission:
adalimumab (Humira®) is accepted for use within NHS Scotland.
Indication under review: treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.
SMC has previously accepted adalimumab for the treatment of active moderate to severe HS (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.
Download detailed advice69KB (PDF)
Medicine details
- Medicine name:
- adalimumab (Humira)
- SMC ID:
- 1243/17
- Indication:
- for treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Skin
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 June 2017